This Plain Language Summary of publication article (PLSP) from Future Oncology discusses the ongoing CROWN study, which compares the effects of two drugs, lorlatinib (Lorbrena) and crizotinib (Xalkori), in people with advanced non-small cell lung cancer (NSCLC) who have not yet been treated. All participants in the study had ALK-positive NSCLC, a genetic alteration that promotes cancer growth. The study evaluates the effectiveness and side effects of these treatments over a 5-year period.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study’ and was published in Journal of Clinical Oncology.

Visit ASCO Publications using the link to read the original article.